Cyclooxygenase and nitric oxide systems in the gut as therapeutic targets for safer anti-inflammatory drugs

Current Opinion in Pharmacology

Volumn 4, Issue 6, 2004, Pages 538-545

  Whittle, Brendan J R ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONATE 5 LIPOXYGENASE; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETORICOXIB; IBUPROFEN; KETOROLAC; LICOFELONE; LUMIRACOXIB; MISOPROSTOL; NAPROXEN; NITRIC OXIDE; NITRONAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARECOXIB; PLACEBO; PROSTAGLANDIN SYNTHASE; PROSTANOID; PROTON PUMP INHIBITOR; ROFECOXIB; THROMBOXANE; VALDECOXIB;

ANTIINFLAMMATORY ACTIVITY; ARTHRALGIA; ARTHROPATHY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COLITIS; CONGESTIVE HEART FAILURE; CROHN DISEASE; DISEASE EXACERBATION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TARGETING; DYSPEPSIA; ENTERITIS; ENTEROPATHY; ENZYME ACTIVITY; ENZYME INHIBITION; GASTRODUODENAL ULCER; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTENSION; LONG TERM CARE; LOW DRUG DOSE; OSTEOARTHRITIS; PATHOGENESIS; PERIPHERAL EDEMA; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SLOW RELEASE FORMULATION; STOMACH INJURY; STOMACH ULCER; ULCERATIVE COLITIS; WOUND INFECTION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DRUG INDUSTRY; GASTROINTESTINAL DISEASES; GASTROINTESTINAL TRACT; HUMANS; MEMBRANE PROTEINS; MULTICENTER STUDIES; NITRIC OXIDE; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES;

EID: 13944259105     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2004.08.003     Document Type: Review

References (49)

1. B.J.R. Whittle Gastrointestinal effects of nonsteroidal anti-inflammatory drugs Fundam Clin Pharmacol 17 2003 301-313
2. T.D. Warner J.A. Mitchell Cyclooxygenases: New forms, new inhibitors, and lessons from the clinic FASEB J 18 2004 790-804
3. J.L. Wallace P. Del Soldato The therapeutic potential of NO-NSAIDs Fundam Clin Pharmacol 17 2003 11-20
4. J. Hoogstraate L.I. Andersson O.G. Berge B. Jonzon G. Ojteg COX-inhibiting nitric oxide donators (CINODs) - a new paradigm in the treatment of pain and inflammation Inflammopharmacology 11 2003 423-428
5. M.W. James C.J. Hawkey Assessment of non-steroidal anti-inflammatory drug (NSAID) damage in the human gastrointestinal tract Br J Clin Pharmacol 56 2003 146-155
6. M.R. Weir R.S. Sperling A. Reicin B.J. Gertz Selective COX-2 inhibition and cardiovascular effects: A review of the rofecoxib development program Am Heart J 146 2003 591-604
7. I. Bjarnason K. Takeuchi R. Simpson The COX controversy. NSAIDs: The emperor's new dogma? Gut 52 2003 1376-1378
8. B.J.R. Whittle The COX controversy: New dogmas or old? Gut 52 2003 1379-1381
9. C.J. Hawkey M.J. Langman Non-steroidal anti-inflammatory drugs: Overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors Gut 52 2003 600-608
10. C.J. Hawkey L. Laine T. Simon H. Quan S. Shingo J. Evans Rofecoxib Rheumatoid Arthritis Endoscopy Study Group: Incidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen, or placebo: A multicentre, randomised, double blind study Gut 52 2003 820-826
11. B. Norgard L. Pedersen S.P. Johnsen R.E. Tarone J.K. McLaughlin S. Friis H.T. Sorensen COX-2-selective inhibitors and the risk of upper gastrointestinal bleeding in high-risk patients with previous gastrointestinal diseases: A population-based case-control study Aliment Pharmacol Ther 19 2004 817-825
12. B.J.R. Whittle Mechanisms underlying intestinal injury induced by anti-inflammatory COX inhibitors Eur J Pharmacol 500 2004 427-439
13. L. Laine L.G. Connors A. Reicin C.J. Hawkey R. Burgos-Vargas T.J. Schnitzer Q. Yu C. Bombardier Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use Gastroenterology 124 2003 288-292
14. A.R. Martin I. Villegas C. La Casa C. Alarcon de la Lastra The cyclo-oxygenase-2 inhibitor, rofecoxib, attenuates mucosal damage due to colitis induced by trinitrobenzene sulphonic acid in rats Eur J Pharmacol 481 2003 281-291
15. W. Reinisch W. Miehsler C. Dejaco M. Harrer T. Waldhoer C. Lichtenberger H. Vogelsang An open-label trial of the selective cyclo-oxygenase-2 inhibitor, rofecoxib, in inflammatory bowel disease-associated peripheral arthritis and arthralgia Aliment Pharmacol Ther 17 2003 1371-1380
16. L. Biancone C. Tosti A. Geremia D. Fina C. Petruzziello S. Emerenziani F. Pallone Rofecoxib and early relapse of inflammatory bowel disease: An open-label trial Aliment Pharmacol Ther 19 2004 755-764
17. D.H. Solomon S. Schneeweiss R. Levin J. Avorn Relationship between COX-2 specific inhibitors and hypertension Hypertension 44 2004 140-145
18. M. Mamdani D.N. Juurlink D.S. Lee P.A. Rochon A. Kopp G. Naglie P.C. Austin A. Laupacis T.A. Stukel Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: A population-based cohort study Lancet 363 2004 1751-1756
19. S. Alsalameh M. Burian G. Mahr B.G. Woodcock G. Geisslinger Review article: The pharmacological properties and clinical use of valdecoxib, a new cyclo-oxygenase-2-selective inhibitor Aliment Pharmacol Ther 17 2003 489-501
20. K. Pavelka D.P. Recker K.M. Verburg Valdecoxib is as effective as diclofenac in the management of rheumatoid arthritis with a lower incidence of gastroduodenal ulcers: Results of a 26-week trial Rheumatology 42 2003 1207-1215
21. J.L. Goldstein A.J. Kivitz K.M. Verburg D.P. Recker R.C. Palmer J.D. Kent A comparison of the upper gastrointestinal mucosal effects of valdecoxib, naproxen and placebo in healthy elderly subjects Aliment Pharmacol Ther 18 2003 125-132
22. L. Rabeneck Measuring dyspepsia-related health in randomized trials: The Severity of Dyspepsia Assessment (SODA) and its use in treatment with NSAIDs and COX-2-specific inhibitors Rheumatology 42 Suppl 3 2003 iii32-iii39
23. S.S. Padi N.K. Jain S. Singh S.K. Kulkarni Pharmacological profile of parecoxib: A novel, potent injectable selective cyclooxygenase-2 inhibitor Eur J Pharmacol 491 2004 69-76
24. J. Barden J.E. Edwards H.J. McQuay R.A. Moore Oral valdecoxib and injected parecoxib for acute postoperative pain: A quantitative systematic review BMC Anesthesiol 3 2003 1-8
25. S.I. Harris R.R. Stoltz D. LeComte R.C. Hubbard Parecoxib sodium demonstrates gastrointestinal safety comparable to placebo in healthy subjects J Clin Gastroenterol 38 2004 575-580
26. E. Ott N.A. Nussmeier P.C. Duke R.O. Feneck R.P. Alston M.C. Snabes R.C. Hubbard P.H. Hsu L.J. Saidman D.T. Mangano Multicenter Study of Perioperative Ischemia (McSPI) Research Group; Ischemia Research and Education Foundation (IREF) Investigators: Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery J Thorac Cardiovasc Surg 125 2003 1481-1492
27. A. Dallob C.J. Hawkey H. Greenberg N. Wight P. De Schepper S. Waldman P. Wong L. DeTora B. Gertz N. Agrawal et al. Characterization of etoricoxib, a novel, selective COX-2 inhibitor J Clin Pharmacol 43 2003 573-585
28. B.R. Rubin R. Burton S. Navarra J. Antigua J. Londono K.G. Pryhuber M. Lund E. Chen D.K. Najarian R.A. Petruschke et al. Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: A randomised controlled trial Arthritis Rheum 50 2004 598-606
29. R.H. Hunt S. Harper D.J. Watson C. Yu H. Quan M. Lee J.K. Evans B. Oxenius The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events Am J Gastroenterol 98 2003 1725-1733
30. R.H. Hunt S. Harper P. Callegari C. Yu H. Quan J. Evans C. James B. Bowen F. Rashid Complementary studies of the gastrointestinal safety of the cyclo-oxygenase-2-selective inhibitor etoricoxib Aliment Pharmacol Ther 17 2003 201-210
31. S.P. Curtis J. Ng Q. Yu S. Shingo G. Bergman C.L. McCormick A.S. Reicin Renal effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs in controlled clinical trials Clin Ther 26 2004 70-83
32. C. Atherton J. Jones B. McKaig J. Bebb R. Cunliffe J. Burdsall J. Brough D. Stevenson J. Bonner C. Rordorf et al. Pharmacology and gastrointestinal safety of lumiracoxib, a novel cyclooxygenase-2 selective inhibitor: An integrated study Clin Gastroenterol Hepatol 2 2004 113-120
33. C. Rordorf N. Kellett S. Mair M. Ford S. Milosavljev J. Branson G. Scott Gastroduodenal tolerability of lumiracoxib vs placebo and naproxen: A pilot endoscopic study in healthy male subjects Aliment Pharmacol Ther 18 2003 533-541
34. S. Smale I. Bjarnason Determining small bowel integrity following drug treatment Br J Clin Pharmacol 56 2003 284-291
35. A.J. Kivitz S. Nayiager T. Schimansky A. Gimona H.J. Thurston C. Hawkey Reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritis Aliment Pharmacol Ther 19 2004 1189-1198
36. C.J. Hawkey M. Farkouh X. Gitton E. Ehrsam J. Huels P. Richardson Therapeutic arthritis research and gastrointestinal event trial of lumiracoxib - study design and patient demographics Aliment Pharmacol Ther 20 2004 51-63
37. M. Marshall P.K. Moore Effect of nitric oxide releasing paracetamol and flurbiprofen on cytokine production in human blood Eur J Pharmacol 483 2004 317-322
38. B. Rigas K. Kashfi Nitric-oxide-donating NSAIDs as agents for cancer prevention Trends Mol Med 10 2004 324-330
39. B. Jonzon I. Bjarnason C. Hawkey J. Jones A. Goddard U. Fagerholm P. Karlsson The CINOD, AZD3582, exhibits an improved gastrointestinal safety profile compared with naproxen in healthy volunteers Inflammopharmacology 11 2003 437-444
40. C.J. Hawkey J.I. Jones C.T. Atherton M.M. Skelly J.R. Bebb U. Fagerholm B. Jonzon P. Karlsson I.T. Bjarnason Gastrointestinal safety of AZD3582, a cyclooxygenase inhibiting nitric oxide donator: Proof of concept study in humans Gut 52 2003 1537-1542
41. NicOx Press Release: NicOx announces positive evaluation of overall phase II clinical results on AZD3582 by a U.S. Consultant Advisory Board. January 27 2004 [http://www.nicox.com/pages/press.asp]
42. Schnitzer TJ, Kivitz AJ, Lipetz S, Sanders N, Hee A: A Phase II study of the efficacy and safety of AZD3582, a CINOD, in subjects with osteoarthritris of the knee. EULAR 2004 Conference, June 2004, Berlin [Abstract OP0016] [URL: http://www.eular.org/index.cfm?framePage=/eular2004.cfm]
43. S.P. Khanapure D.S. Garvey D.V. Young M. Ezawa R.A. Earl R.D. Gaston X. Fang M. Murty A. Martino M. Shumway et al. Synthesis and structure-activity relationship of novel, highly potent metharyl and methcycloalkyl cyclooxygenase-2 (COX-2) selective inhibitors J Med Chem 46 2003 5484-5504
44. R.R. Ranatunge D.S. Garvey D.R. Janero L.G. Letts A.M. Martino M.G. Murty S.K. Richardson D.V. Young I.S. Zemetseva Synthesis and selective cyclooxygenase-2 (COX-2) inhibitory activity of a series of novel bicyclic pyrazoles Bioorg Med Chem 12 2004 1357-1366
45. R.R. Ranatunge M. Augustyniak U.K. Bandarage R.A. Earl J.L. Ellis D.S. Garvey D.R. Janero L.G. Letts A.M. Martino M.G. Murty et al. Synthesis and selective cyclooxygenase-2 inhibitory activity of a series of novel, nitric oxide donor-containing pyrazoles J Med Chem 47 2004 2180-2193
46. J.M. Alvaro-Gracia Licofelone-clinical update on a novel LOX/COX inhibitor for the treatment of osteoarthritis Rheumatology 43 Suppl 1 2004 i21-i25
47. P. Bias A. Buchner B. Klesser S. Laufer The gastrointestinal tolerability of the LOX/COX inhibitor, licofelone, is similar to placebo and superior to naproxen therapy in healthy volunteers: Results from a randomized, controlled trial Am J Gastroenterol 99 2004 611-618
48. A. Weber A. Casini A. Heine D. Kuhn C.T. Supuran A. Scozzafava G. Klebe Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: New pharmacological opportunities due to related binding site recognition J Med Chem 47 2004 550-557
49. J.M. Lehtonen S. Parkkila D. Vullo A. Casini A. Scozzafava C.T. Supuran Carbonic anhydrase inhibitors. Inhibition of cytosolic isozyme XIII witharomatic and heterocyclic sulfonamides: A novel target for the drug design Bioorg Med Chem Lett 14 2004 3757-3762